Bruker (NASDAQ:BRKR) Price Target Cut to $69.00 by Analysts at Barclays

Bruker (NASDAQ:BRKR) had its price objective reduced by Barclays from $75.00 to $69.00 in a report issued on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

Several other brokerages also recently issued reports on BRKR. Citigroup reduced their price target on shares of Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. The Goldman Sachs Group decreased their target price on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. Wells Fargo & Company assumed coverage on Bruker in a report on Tuesday, August 27th. They set an “overweight” rating and a $78.00 price target on the stock. TD Cowen decreased their price objective on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a report on Wednesday, August 7th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $79.36.

Bruker Price Performance

Shares of BRKR opened at $57.73 on Wednesday. Bruker has a 52 week low of $54.55 and a 52 week high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.75 and a debt-to-equity ratio of 1.24. The firm has a market cap of $8.74 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.83 and a beta of 1.20. The stock has a 50 day moving average of $63.64 and a 200-day moving average of $66.21.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same period in the prior year, the firm earned $0.74 EPS. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. As a group, analysts forecast that Bruker will post 2.39 EPS for the current year.

Institutional Investors Weigh In On Bruker

A number of large investors have recently bought and sold shares of BRKR. Marshall Wace LLP raised its stake in shares of Bruker by 127.8% in the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after acquiring an additional 779,549 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Bruker during the second quarter valued at approximately $36,472,000. AQR Capital Management LLC raised its position in shares of Bruker by 123.6% in the second quarter. AQR Capital Management LLC now owns 555,468 shares of the medical research company’s stock valued at $35,444,000 after purchasing an additional 307,021 shares during the period. Vaughan Nelson Investment Management L.P. lifted its stake in shares of Bruker by 78.3% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 593,091 shares of the medical research company’s stock worth $37,845,000 after buying an additional 260,363 shares during the last quarter. Finally, Point72 Europe London LLP boosted its holdings in shares of Bruker by 262.9% during the 2nd quarter. Point72 Europe London LLP now owns 333,997 shares of the medical research company’s stock worth $21,312,000 after buying an additional 241,959 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.